Multiple Sclerosis, Relapsing-Remitting — Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis (RRMS)
Citation(s)
Alonso-Ortiz E, Levesque IR, Pike GB MRI-based myelin water imaging: A technical review. Magn Reson Med. 2015 Jan;73(1):70-81. doi: 10.1002/mrm.25198. Epub 2014 Mar 6. Review.
Barkhof F, Calabresi PA, Miller DH, Reingold SC Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol. 2009 May;5(5):256-66. doi: 10.1038/nrneurol.2009.41. Review.
Bernini GP, Lucarini AR, Franchi F, Salvetti A Humoral effects of metoclopramide and domperidone in normal subjects and in hypertensive patients. J Endocrinol Invest. 1988 Nov;11(10):711-6.
Bjartmar C, Kidd G, Mörk S, Rudick R, Trapp BD Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol. 2000 Dec;48(6):893-901.
Mi S, Pepinsky RB, Cadavid D Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic. CNS Drugs. 2013 Jul;27(7):493-503. doi: 10.1007/s40263-013-0068-8. Review.
Sloka S, Metz LM, Hader W, Starreveld Y, Yong VW Reduction of microglial activity in a model of multiple sclerosis by dipyridamole. J Neuroinflammation. 2013 Jul 18;10:89. doi: 10.1186/1742-2094-10-89.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
